Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
ESEstrella Immunopharma, Inc. logo

Estrella Immunopharma, Inc. (ESLA)

NASDAQ Capital Market · Currency in USD
$0.99 ▲ +0.26 (+35.53%)
At close: Oct 23, 4:00 PM ET. Market closed.
$0.96 ▼ -0.02 (-2.14%)
After hours: Oct 23, 7:57 PM ET

Summary

Previous Close
$0.73
Open
$0.75
Day's Range
$0.75 – $1.00
52 Week Range
$0.24 – $3.15
Volume
3,648,822
Avg. Volume
1,195,047
Market Cap
$42.85M
Beta (5Y Monthly)
0.93
PE Ratio (TTM)
--
EPS (TTM)
-$0.23
Earnings Date
Dec 2, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: Estrella Immunopharma, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
3
CEO
Cheng Liu

Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103.

Earnings

Next report: Wed, Dec 2, 2026
EPS estimate -$0.08
DateEst.Actual
Aug 13, 2026-$0.05-$0.05Beat
May 13, 2026-$0.08-$0.05Beat
Mar 18, 2026-$0.18-$0.14Beat
Nov 12, 2025-$0.19-$0.13Beat
Aug 11, 2025-$0.07-$0.15Miss
May 14, 2025-$0.11-$0.06Beat

Analyst view

Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on ESLA and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.